These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18508636)

  • 1. Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.
    Peng CT; Chang JS; Wu KH; Tsai CH; Lin HS
    Front Biosci; 2008 May; 13():5975-87. PubMed ID: 18508636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiology and pathophysiology of iron cardiomyopathy in thalassemia.
    Wood JC; Enriquez C; Ghugre N; Otto-Duessel M; Aguilar M; Nelson MD; Moats R; Coates TD
    Ann N Y Acad Sci; 2005; 1054():386-95. PubMed ID: 16339687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.
    Pennell DJ; Udelson JE; Arai AE; Bozkurt B; Cohen AR; Galanello R; Hoffman TM; Kiernan MS; Lerakis S; Piga A; Porter JB; Walker JM; Wood J;
    Circulation; 2013 Jul; 128(3):281-308. PubMed ID: 23775258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalassemia.
    Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
    Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron and oxidative stress in cardiomyopathy in thalassemia.
    Berdoukas V; Coates TD; Cabantchik ZI
    Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congestive heart failure and treatment in thalassemia major.
    Aessopos A; Kati M; Tsironi M
    Hemoglobin; 2008; 32(1-2):63-73. PubMed ID: 18274984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
    Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
    Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac complications in beta-thalassemia: From mice to men.
    Kumfu S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1126-1135. PubMed ID: 28485683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
    Martín M; Estornell J; Orero M; Pérez JL; Ridocci F; Martínez V
    Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    Expert Rev Hematol; 2018 Jun; 11(6):471-479. PubMed ID: 29754517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cardiac function in patients with thalassemia major.
    Nienhuis AW; Griffith P; Strawczynski H; Henry W; Borer J; Leon M; Anderson WF
    Ann N Y Acad Sci; 1980; 344():384-96. PubMed ID: 6930878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased sympathovagal imbalance evaluated by heart rate variability is associated with decreased T2* MRI and left ventricular function in transfusion-dependent thalassemia patients.
    Pattanakuhar S; Phrommintikul A; Tantiworawit A; Konginn S; Srichairattanakool S; Chattipakorn SC; Chattipakorn N
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29330222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.